Clinical Trial Update: Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis [Phase 2]

View source ↗

Summary

Phase 2 dose-response study for GSK2330672 in pruritus associated with primary biliary cholangitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis
• Cholestasis

Drugs mentioned

• GSK2330672

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cholestasis | Phase 2 | Status: COMPLETED | Results posted: 2021-05-04